SUBSCRIBE
SUBSCRIBE

Phase 3

Drug Development
Clinical Trial Registration: Looking Back and Moving Ahead
August 22, 2007
 · 
1 min read
Drug Development
Andromeda Phase III Trial Costs Weigh on Andromeda Results
August 20, 2007
 · 
1 min read
Drug Development
Sentara One Step Closer to Breast Cancer Clinical Trial
August 16, 2007
 · 
1 min read
Drug Development
Institutional Review Boards Should Require Clinical Trial Registration
August 15, 2007
 · 
1 min read
Drug Development
Trial Practitioners Must Become Media Savvy
August 14, 2007
 · 
1 min read
Drug Development
South Africa: HIV Trial Gets Long-Awaited Go Ahead
August 10, 2007
 · 
1 min read
Drug Development
E-Data Can Transform Clinical Trials
August 9, 2007
 · 
1 min read
Drug Development
Pima Community College Offers New Clinical Trials Programs
August 8, 2007
 · 
1 min read
Drug Development
Court Rules Out Terminally Ill for Tests
August 8, 2007
 · 
1 min read
Drug Development
Firms Should Still Carefully Consider Audit Trails for Clinical Trial Systems
August 6, 2007
 · 
1 min read
Load More
PRESS RELEASES
Press Releases
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
February 27, 2026
 · 
7 min read
Press Releases
Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
February 27, 2026
 · 
6 min read
Press Releases
ADARx Pharmaceuticals Presents Onvuzosiran Data Supporting Potential for Sustained Attack-Free Rates with Reduced Treatment Burden in Patients with HAE
February 27, 2026
 · 
4 min read
Press Releases
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
February 27, 2026
 · 
10 min read
Press Releases
Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
February 27, 2026
 · 
12 min read
Press Releases
Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates
February 27, 2026
 · 
13 min read
Press Releases
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026
 · 
15 min read
Press Releases
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
February 26, 2026
 · 
7 min read
Press Releases
OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer
February 26, 2026
 · 
3 min read
Press Releases
Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress
February 26, 2026
 · 
6 min read
Press Releases
Tris Pharma to Present Debut Data from Phase 3 ALLEVIATE 1-2 Trials Evaluating Cebranopadol in Acute Pain at AAPM PainConnect 2026 Annual Meeting
February 26, 2026
 · 
4 min read
Press Releases
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
February 26, 2026
 · 
7 min read
Press Releases
Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
February 26, 2026
 · 
10 min read
Press Releases
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
February 26, 2026
 · 
13 min read
Press Releases
InnoCare Announces Key Developments of Critical Clinical Studies
February 26, 2026
 · 
3 min read
Press Releases
MindRank Announces First Patient Dosed in Phase III Trial of AI-Designed Oral GLP-1 Receptor Agonist MDR-001
February 26, 2026
 · 
3 min read
Press Releases
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026
February 26, 2026
 · 
19 min read
Press Releases
Pritelivir Demonstrates Superior Efficacy in People Living with HIV with Refractory HSV in Phase 3 PRIOH-1
February 26, 2026
 · 
6 min read
Press Releases
ITM to Announce Phase 3 COMPETE Trial Post-Hoc Subgroup Analysis in Pancreatic Neuroendocrine Tumors and Host Satellite Symposium at ENETS 2026
February 25, 2026
 · 
3 min read
Press Releases
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
February 25, 2026
 · 
7 min read
Load More